Sabby Management’s Sonnet BioTherapeutics SONN Stock Holding History

Sabby Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-29,799	Closed	-$223K	–	60
2024 Q2	$223K	Buy	+29,799	New	+$402K	0.15%	18
2023 Q3	–	Sell	-18,699	Closed	-$1.61M	–	104
2023 Q2	$1.61M	Buy	18,699 +11,793	+171%	+$832K	1.32%	5
2023 Q1	$438K	Buy	+6,906	New	+$1.12M	0.38%	25

Other funds holding SONN

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $381M AUM 19.19% 1-Year Est. Return

Sabby Management's SONN Position: Q3 2024 in Review

Sabby Management sold out of Sonnet BioTherapeutics (SONN) in Q3 2024, closing a stake of 29,799 shares — an estimated $223K sold.

Sabby Management first reported a position in SONN in Q1 2023 and held it in 3 quarters. The position peaked at $1.61M in Q2 2023. 2 funds tracked by Wall St. Rank hold SONN as of Q3 2024.

Sabby Management reported no remaining Sonnet BioTherapeutics position as of Q3 2024 after selling out during the quarter.
Sabby Management sold 29,799 Sonnet BioTherapeutics shares in Q3 2024, an estimated $223K.
Sabby Management first reported a position in Sonnet BioTherapeutics in Q1 2023 and held it in 3 quarters.
Sabby Management's Sonnet BioTherapeutics position peaked at $1.61M in Q2 2023.
2 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2024.

Based on Sabby Management's 13F filing for Q3 2024, filed 14 Nov 2024.